Bristol-Myers Squibb Weighs Options On Mead Johnson
This article was originally published in The Tan Sheet
Executive Summary
Bristol-Myers Squibb could reap as much as $10 billion by selling its Mead Johnson nutritional business and other non-pharmaceutical units, analysts say
You may also be interested in...
BMS Spins Off Mead Johnson In IPO, Retaining Majority Control
Bristol-Myers Squibb will spin off its Mead Johnson infants and children nutritional products business in an initial public offering of shares rather than sell the unit, the firm says
BMS Spins Off Mead Johnson In IPO, Retaining Majority Control
Bristol-Myers Squibb will spin off its Mead Johnson infants and children nutritional products business in an initial public offering of shares rather than sell the unit, the firm says
BMS Spins Off Mead Johnson In IPO, Retaining Majority Control
Bristol-Myers Squibb will spin off its Mead Johnson infants and children nutritional products business in an initial public offering of shares rather than sell the unit, the firm says